WallStreetZenWallStreetZen

NASDAQ: VBLT
Vascular Biogenics Ltd Stock

$0.17+0.00 (+0%)
Updated Mar 29, 2023
VBLT Price
$0.17
Fair Value Price
$0.40
Market Cap
$11.72M
52 Week Low
$0.10
52 Week High
$2.20
P/E
0.4x
P/B
0.52x
P/S
14.14x
PEG
0.21x
Dividend Yield
N/A
Revenue
$658.00k
Earnings
-$32.30M
Gross Margin
84.2%
Operating Margin
-4,896.5%
Profit Margin
-4,909.4%
Debt to Equity
0.32
Operating Cash Flow
-$32M
Beta
0.92
Next Earnings
May 15, 2023
Ex-Dividend
N/A
Next Dividend
N/A

VBLT Overview

Vascular Biogenics Ltd., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. Its programs are based on its vascular targeting system, a gene-based technology targeting newly formed blood vessels; and monocyte targeting technology, an antibody-based technology that enables specifically inhibit monocyte migration for immune-inflammatory applications. The company's lead product candidate is VB-111, a gene-based biologic that is in Phase III clinical trials for the recurrent platinum-resistant ovarian cancer; and Phase II clinical trials treatment of recurrent glioblastoma and colorectal cancer, as well as has completed Phase II clinical trial for the treatment of thyroid cancer. It is also developing VB-601 for various inflammatory indications, and VB-611 for various solid tumors. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi'in, Israel.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how VBLT scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

VBLT ($0.17) is undervalued by 57.54% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
VBLT ($0.17) is significantly undervalued by 57.54% relative to our estimate of its Fair Value price of $0.40 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
VBLT ($0.17) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more VBLT due diligence checks available for Premium users.

Be the first to know about important VBLT news, forecast changes, insider trades & much more!

VBLT News

Valuation

VBLT fair value

Fair Value of VBLT stock based on Discounted Cash Flow (DCF)
Price
$0.17
Fair Value
$0.40
Undervalued by
57.04%
VBLT ($0.17) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
VBLT ($0.17) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
VBLT ($0.17) is trading below... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

VBLT price to earnings (PE)

For valuing profitable companies with steady earnings
Company
0.4x
Industry
18.17x
Market
21.81x
VBLT is good value based... subscribe to Premium to read more.
P/E vs Industry Valuation
VBLT is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

VBLT price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.52x
Industry
4.92x
VBLT is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

VBLT price to earnings growth (PEG)

For valuing profitable companies with growth potential
VBLT is good value based... subscribe to Premium to read more.
PEG Value Valuation

VBLT's financial health

Profit margin

Revenue
$0.0
Net Income
-$3.3M
Profit Margin
0%
VBLT's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
VBLT's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$29.7M
Liabilities
$7.2M
Debt to equity
0.32
VBLT's short-term assets ($22.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VBLT's short-term assets ($22.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VBLT's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
VBLT's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$6.7M
Investing
$6.0M
Financing
$0.0
VBLT's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

VBLT vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
VBLT$11.72M-1.18%0.40x0.52x
APGN$11.70M+0.64%-0.29x1.84x
CING$11.65M-0.96%-0.66x3.00x
APRE$12.06M-1.30%-0.04x0.45x
GLMD$11.34M+4.90%-0.63x0.84x

Vascular Biogenics Stock FAQ

What is Vascular Biogenics's quote symbol?

NASDAQ: VBLT) Vascular Biogenics trades on the NASDAQ under the ticker symbol VBLT. Vascular Biogenics stock quotes can also be displayed as NASDAQ: VBLT.

If you're new to stock investing, here's how to buy Vascular Biogenics stock.

What is the 52 week high and low for Vascular Biogenics (NASDAQ: VBLT)?

(NASDAQ: VBLT) Vascular Biogenics's 52-week high was $2.20, and its 52-week low was $0.10. It is currently -92.36% from its 52-week high and 66.34% from its 52-week low.

How much is Vascular Biogenics stock worth today?

(NASDAQ: VBLT) Vascular Biogenics currently has 69,750,117 outstanding shares. With Vascular Biogenics stock trading at $0.17 per share, the total value of Vascular Biogenics stock (market capitalization) is $11.72M.

Vascular Biogenics stock was originally listed at a price of $5.85 in Oct 1, 2014. If you had invested in Vascular Biogenics stock at $5.85, your return over the last 8 years would have been -97.13%, for an annualized return of -35.84% (not including any dividends or dividend reinvestments).

How much is Vascular Biogenics's stock price per share?

(NASDAQ: VBLT) Vascular Biogenics stock price per share is $0.17 today (as of Mar 29, 2023).

What is Vascular Biogenics's Market Cap?

(NASDAQ: VBLT) Vascular Biogenics's market cap is $11.72M, as of Mar 30, 2023.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Vascular Biogenics's market cap is calculated by multiplying VBLT's current stock price of $0.17 by VBLT's total outstanding shares of 69,750,117.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.